Latest Regulatory News

Alterity Therapeutics has raised A$20 million through a strategic placement to advance its promising ATH434 treatment for Multiple System Atrophy, backed by encouraging Phase 2 trial results. The capital injection strengthens the company’s balance sheet as it prepares for regulatory discussions with the FDA.

PolarX Limited's trading suspension has been lifted immediately following its announcement of a new capital raising, signaling renewed market activity for the mining explorer.

Coles Group reveals a significant potential financial impact following a Federal Court decision on underpayments to salaried team members, estimating remediation costs between $150 million and $250 million.

The Takeovers Panel has approved a key variation to betr Entertainment’s undertaking, removing shareholder approval hurdles for MIXI Australia’s participation in a selective share buy-back tied to its competing bid for PointsBet.

EMU NL has announced a non-renounceable entitlement offer to raise approximately $1.83 million to fund exploration at its Georgetown and Badja projects, while facing significant governance challenges ahead of a pivotal shareholder meeting.

Trigg Minerals has completed a conceptual study for a cutting-edge antimony smelter using Metso’s Ausmelt technology, aiming to establish a rare mine-to-metal supply chain in the West. The project promises energy efficiency, environmental responsibility, and rapid development to meet growing US demand.

333D Limited has ended its voluntary suspension, confirming its Bitcoin acquisitions align with ASX rules and outlining a disciplined treasury management strategy to support operational cash flow and growth.

BetMakers Technology Group has met the initial performance hurdle of its Long-Term Incentive Plan, triggering the conversion of 5 million performance rights into shares and signaling strong operational momentum.

Imagion Biosystems has reached key milestones in its MagSense® HER2 breast cancer imaging program, including starting manufacturing for its Phase 2 trial and launching an AI imaging protocol collaboration with Wayne State University.

Ausbil Investment Management has launched the Ausbil Active Dividend Income Fund – Active ETF, targeting tax effective income and potential capital growth through an actively managed Australian equities portfolio. The Fund will trade on the ASX AQUA market under ticker DIVI, featuring a 0.85% management fee and monthly distributions.

Boab Metals has extended its option to acquire full ownership of the Sorby Hills Project to the end of 2025, while locking in critical commercial agreements and environmental approvals that pave the way for a final investment decision.

Orthocell Limited reports an 81.1% overall treatment success rate from its Remplir Real World Evidence study, reinforcing the product’s safety and efficacy as it expands sales in the US and prepares regulatory submissions for the EU and UK.